Advanced Search

Show simple item record

dc.contributor.authorKarcıoğlu, Özgür
dc.contributor.authorAfacan, Göksu
dc.contributor.authorÖzkaya, Bilgen
dc.contributor.authorYılmaz, Ebru
dc.contributor.authorErsan, Eylem
dc.contributor.authorYeniocak, Selman
dc.contributor.authorHosseinzadeh, Mandana
dc.date.accessioned2020-10-27T05:35:11Z
dc.date.available2020-10-27T05:35:11Z
dc.date.issued12.09.2020en_US
dc.identifier.issn2456-9119
dc.identifier.urihttps://hdl.handle.net/20.500.12445/1392
dc.description.abstractIt is well established that cytokine storm is associated with more severe clinical course of COVID19. Many clinical findings of COVID-19 and other severe viral infections (e.g. fever, muscle pain, respiratory distress, cough), are directly attributed to cytokine storm. For example, IL-6 and IL-10 can be used as predictors for expedient diagnosis of patients with higher risk of deterioration. Hyper-inflammatory status in patients with severe COVID-19 is to be mitigated to alleviate signs and symptoms in cytokine storm. In case of deterioration of oxygenation and rapid progression of imaging (CT) findings, glucocorticoids can be used for a short time (3-5 days) for patients in whom overactivation of the body's inflammatory response is suspected. On the other hand, interleukin-6 receptor antibodies tocilizumab, sarilumab, siltuximab can be used as immunomodulators, to suppress inflammation and to alleviate fever and other manifestations of immune response. Their beneficial efficacy is especially remarkable during the cytokine storm period. It should be kept in mind that the agents to be used in the management of any given patient should be tailored for each situation.en_US
dc.description.abstractIt is well established that cytokine storm is associated with more severe clinical course of COVID19. Many clinical findings of COVID-19 and other severe viral infections (e.g. fever, muscle pain, respiratory distress, cough), are directly attributed to cytokine storm. For example, IL-6 and IL-10 can be used as predictors for expedient diagnosis of patients with higher risk of deterioration. Hyper-inflammatory status in patients with severe COVID-19 is to be mitigated to alleviate signs and symptoms in cytokine storm. In case of deterioration of oxygenation and rapid progression of imaging (CT) findings, glucocorticoids can be used for a short time (3-5 days) for patients in whom overactivation of the body's inflammatory response is suspected. On the other hand, interleukin-6 receptor antibodies tocilizumab, sarilumab, siltuximab can be used as immunomodulators, to suppress inflammation and to alleviate fever and other manifestations of immune response. Their beneficial efficacy is especially remarkable during the cytokine storm period. It should be kept in mind that the agents to be used in the management of any given patient should be tailored for each situation.en_US
dc.language.isoengen_US
dc.publisherJournal of Pharmaceutical Research Internationalen_US
dc.publisherTürkiye Kliniklerien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectCytokine Stormen_US
dc.subjectCytokine Stormen_US
dc.subjectCorticosteroidsen_US
dc.subjectCorticosteroidsen_US
dc.subjectInterleukin-6 Receptor Antibodiesen_US
dc.subjectInterleukin-6 Receptor Antibodiesen_US
dc.subjectTocilizumaben_US
dc.subjectTocilizumaben_US
dc.subjectAntiinflammatory Treatmenten_US
dc.subjectAntiinflammatory Treatmenten_US
dc.subjectCOVID-19en_US
dc.subjectCOVID-19en_US
dc.titleCytokine storm, corticosteroids and interleukin-6 receptor antibodies in context of antiinflammatory treatment in COVID-19en_US
dc.typearticleen_US
dc.relation.journalJournal of Pharmaceutical Research Internationalen_US
dc.contributor.departmentTıp Fakültesien_US
dc.identifier.volume32en_US
dc.identifier.issue25en_US
dc.identifier.startpage67en_US
dc.identifier.endpage75en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess